The irst umbilical cord blood (UCB) transplant (UCBT) by
Gluckman et al. was performed in 1988 in a patient with Fanconi's anemia. (1) This patient had a healthy human leukocyte antigen (HLA)-identical sibling who was shown by prenatal testing to be unaffected by the disorder, to have a normal karyotype and to be HLA identical to the patient.
Her cord blood was collected at birth, cryopreserved and used after thawing for transplantation. Since the irst UCBT, more than 20,000 UCBTs have been reported worldwide and more than 620,000 UCB units have been stored in more than 100 UCB banks. (2) The main practical advantages of using UCB as an alternative source of stem cells are the relative ease of procurement, the absence of risks for mothers and donors, the reduced likelihood of transmitting infections, particularly cytomegalovirus (CMV) and the ability to store fully tested and HLA-typed transplants in the frozen state, available for immediate use (3) .
UCB bank (UCBB) established criteria for standardization of UCB collection, banking, processing and cryopreservation for unrelated donor transplants in patients with various hematological malignant and non-malignant diseases. (3) Recently, the use of UCB stem cells (UCB-SCs) in several regenerative medicine applications has expanded its clinical utility.
UCB-SCs contains a mixture of multipotent stem cells capable of giving rise to cells derived from the endodermal, mesodermal and ectodermal lineages. It has been shown that UCB-SCs have the ability to regenerate numerous tissue types, and when transplanted into animals and humans, have produced measurable functional improvements. (4, 5) Generally, tissue-derived stem cells have been described for neural (6) , retinal (7), pancreas (8) , skin (9) and liver tissues (10) . UCB-SCs appear to be unique in their ability to undergo pluripotential differentiation. Thus, UCB-SCs appear to be a practical substitute for embryonic stem cells and are readily available for use in tissue engineering and regenerative medicine. Recently clinical trials have begun using UCB-SCs to treat type 1 diabetes mellitus (T1DM), cerebral palsy and peripheral vascular disease among others. (4,5) UCB-SCs has transitioned from the laboratory to the clinic and numerous patients are currently being treated in clinical trials. Other trials will surely rapidly follow, including therapies for eyes, joints, wound and spinal cord.
The key to these advances lies in the pluripotency of UCBSCs and their ability to be used in many instances under the practice of medicine, as it appears in many instances that it Introduction is possible to merely infuse the stem cells directly without timely and costly in vitro culture and differentiation. (11) Hematopoietic stem cell (HSC) transplantation (HSCT) can be performed using stem cells derived from three sources: bone marrow (BM), peripheral blood (PB) and UCB. Only about 30% of patients in need of HSCT have a matchedrelated donor and, although there are currently around 10 million adult volunteer donors registered worldwide, still about 60% of patients will not ind a suitably HLA-matched unrelated adult donor, and thus cannot access this potentially curative therapy. (12) As UCB products are HLA-typed, tested for lack of infectious agents and stored, they are immediately available upon request and can be shipped to any transplant center in the world with relative ease and without delay. (13, 14) UCB has become such a popular adult stem cell source for many reasons, not least because over 130 million births worldwide per annum represents the largest, easily available stem cell source. It also allows for storage of units from ethnic minorities not easily possible within BM registries. 
UCB-SCs
stored globally in the last 10 years. Already, over 20,000 transplants been performed using UCB for haematopoietic reconstitution alone, now this potential is joined in the regenerative medicine. (21) UCBB has gained signiicant interest in recent years because of the success of UCBT and its more recent applications within regenerative medicine. Both public and private banking facilities have been established over the past 20 years to facilitate these endeavors.
Generally, UCB samples are red cell-and volumereduced prior to cryopreservation, in order to facilitate banking and minimize costs. Samples may be frozen using a variety of media, and can be stored in either cryovials or cryobags, generally in a limited number of frozen aliquots. The storage containers may also be overwrapped with a plastic protective sheath for protection from contact with the liquid nitrogen (LN 2 ) itself, as well as a barrier to sample contamination. (24) Two of the most critical steps in the banking process are the cryopreservation and long-term LN 2 storage of the sample in such a fashion that the sample will be viable and usable decades into the future. (24) Finally, great concern was raised in the mid-1990s
over potential cross-sample contamination during liquidphase LN 2 storage, after the demonstration that pathogenic viruses and other microbial pathogens could survive longterm direct contact with LN 2 and could infect other samples stored in the same dewar. (25, 26) While donor-speciic factors probably impact on the potency of a UCB unit (27) , the collection, processing, distribution and infusion stages may also affect the potency of this stem cell product, whatever processing technology a laboratory chooses, the goal is to achieve maximal recovery of total nucleated cells (TNC), mononuclear cells (MNCs), CD34 + cells, CFU, progenitor cells and stem cells.(28) While the overall cellular recovery declines as a result of the freezing process, the overall potency may be preserved for more than 15 years if the UCB is maintained below -150°C. (29) Currently the United States Food and Drug Administration (US FDA) recommends evaluation of potency through assessment of the following in vitro assays: TNC count, cell viability and CD34 analysis. TNC are measured using automated hematology analyzers, the CD34 assay is performed using low cytometry, and the CFU assay is accomplished using a methylcellulose-based media impregnated with cytokines. (28) There is increasing evidence that UCB unit potency should be assessed postcryopreservation because events associated with freezing and storage can affect subsequent cellular viability and overall UCB potency. (28) Although there are many beneits to using UCB for transplantation there is one major limitation: the TNC count and cell number recoverable from a single unit. This is affected by unit size, maternal factors such as number of previous pregnancies and age of mother (30) , limited volumes available from each sample, but not least the processing method used. Together, these factors highlight the need to make processing as eficient as possible (31) to make UCBB a real option. Many methods are currently available. Techniques were varied; from density gradient separation, like Lymphoprep or Ficoll-Paque (32), rouleaux formation using Hetastarch (HES), a starch based method causing red cells to clump (33) , plasma depletion; a simple volume reduction method which avoids the addition of any chemicals and simply removes the plasma (34), a novel closed separation kit, known as PrepaCyte-CB which offers rapid and speciic cell separation (35) , and the only fully automated system, provided by Biosafe, known as the 'Sepax' machine (36 Neonatal hypoxic ischemic (HI) encephalopathy due to perinatal asphyxia is an important cause of death in the neonatal period, in both developing and developed countries.(72) Among the surviving infants, up to 25% will have a permanent neurologic deicit in the form of cerebral palsy, epilepsy, learning disability, or mental retardation. (73) Treatment is currently limited to supportive intensive care. Given the severity of the problem, it is necessary to ind new approaches that could reduce the neurologic sequelae of HI newborns (74) .
In the last few years, preclinical studies have shown that UCB-SCs injected systemically in the acute phase of animal models of stroke, have a therapeutic effect. These (76) . The potential of UCB-SCs to reduce the neurologic deicits associated with neonatal hypoxia-ischemia was shown in rats in a study that assessed the functional beneits of these cells, using a walking-pattern analysis test. The UCB-SCs, when injected intraperitoneally 24 hours after the insult, migrated to areas of brain damage in large numbers, and alleviated the spastic paresis of the animals. (77) with her eyes and lift her arms and legs high in the air. Eventually, two of the three medications she was on were discontinued. Jordan's story has appeared in numerous regional and national newspapers, and also has been the focus of TV coverage in Missisippi. (97) 
UCB-SCs for
Non-Hematological Disorders cells can reduce the area of brain infarction (75) and the inlammation, and increase the regenerative capacity of the brain, improving behavioral recovery
Conclusion
In the last few years, pure UCB-SCs have been utilized by physicians to treat a multitude of intractable diseases such as progressive MS, ALS, macular degeneration, retinitis pigmentosa, stroke, diabetes, and various forms of heart disease. This body of patient responses indicates that UCB-SCs therapy does produce clinically signiicant improvements in many instances. While certainly no cure for all, UCB-SC therapy appears to be amassing a respectable track record in terms of both safety and clinical utility. 
